Parse Biosciences, a leader in scalable single-cell sequencing solutions, today announced the expansion of its Evercode BCR™ product line to support mouse applications. The new kits allow researchers to profile the mouse BCR repertoire alongside whole transcriptome data for millions of cells in a single experiment, providing unparalleled scale and efficiency for antibody discovery.
Parse Biosciences, a leader in scalable single-cell sequencing solutions, has expanded its Evercode BCR™ platform to support research in mice. This advancement enables researchers to profile the mouse BCR repertoire alongside whole transcriptome data from millions of cells in a single experiment. The technology promises to accelerate antibody discovery with unmatched scale and efficiency. By incorporating unique features such as sample fixation capabilities, Evercode BCR allows researchers to preserve cells and samples from mice for up to six months, reducing the need for additional animal harvesting and maximizing the yield from each discovery campaign. Additionally, the platform eliminates the need for costly equipment, making high-level single-cell analysis accessible with standard laboratory tools.
The Evercode BCR platform provides comprehensive profiling of BCR clonotype diversity and VDJ gene usage frequencies, offering a deeper understanding of antibody responses. Its high pairing rate for immunoglobulin heavy and light chains ensures precise antibody analysis. Furthermore, the technology excels at detecting rare populations, such as plasma cells, by using gentle fixation methods and advanced combinatorial cell barcoding techniques.
“With the expansion of Evercode BCR to include studies in mice, researchers can now fully characterize immune responses in disease-specific mouse models and speed up their antibody discovery processes,” said Charlie Roco, Chief Technology Officer and co-founder of Parse Biosciences. “We are eager to see the significant impact this will have on immunology and antibody-based drug discovery.”
Dan Rohrer, CTO of AbTherx, an early access user, expressed enthusiasm about the product’s potential: “It’s exciting to see Evercode BCR successfully applied to transgenic mouse B cell analysis for the first time. We believe Parse’s technology will allow for in-depth analysis of Atlas™ B cell lineages and compartmental studies, driving outstanding performance in antibody diversity and hit generation.”
Parse Biosciences will present Evercode BCR at the Antibody Engineering & Therapeutics (AET) conference in San Diego, December 15-18. Attendees can learn more during their spotlight talk, “Deep Mining of Antibody Repertoires with Single Cell B Cell Sequencing Tools.”
About Parse Biosciences
Parse Biosciences is a global leader in life sciences, committed to accelerating human health and scientific research. The company’s groundbreaking approach enables large-scale single-cell sequencing, empowering researchers in areas like cancer treatment, tissue repair, stem cell therapy, and immune system studies. Founded by Alex Rosenberg and Charles Roco at the University of Washington, Parse has raised over $100 million in capital and serves more than 2,000 customers worldwide. Its product portfolio includes Evercode™ Whole Transcriptome, Evercode™ TCR, Evercode™ BCR, Gene Select, and Trailmaker™, a solution for data analysis. The company is headquartered in Seattle’s South Lake Union district.
